IRD
Opus Genetics, Inc.Company Information
- Company Name
- Opus Genetics, Inc.
- CIK
- CIK0001228627
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- IRD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IRD
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-29
- Last sale
- 2026-09-03
- Shares purchased (TTM)
- 81,000
- Shares sold (TTM)
- 5,830,726
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 57,609,851
- Shares outstanding
- 95,483,280
- Ownership
- 60.34%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -0.81%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 35 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Nonrelated Party | 35 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 89 | 60 | 45 | 31 | 32 | 42 | 30 | 37 | 41 | 47 | 51 | 42 | ||||||
| Accounts Receivable Net Current | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 2 | 1 | 2 | 1 | 10 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 4 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | ||||||
| Short Term Investments | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 93 | 67 | 50 | 36 | 38 | 48 | 37 | 40 | 45 | 52 | 54 | 54 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 93 | 67 | 50 | 36 | 39 | 48 | 37 | 40 | 45 | 52 | 54 | 54 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 4 | 3 | 2 | 1 | 2 | 3 | 1 | 1 | 2 | 2 | 2 | ||||||
| Accrued Liabilities And Other Liabilities | 6 | 5 | 4 | 5 | 7 | 9 | 8 | - | - | - | - | - | ||||||
| Derivative Liabilities Current | - | - | - | 21 | 12 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | - | - | 4 | - | - | - | 8 | 5 | 3 | 4 | 2 | 2 | ||||||
| Liabilities Current | 8 | 9 | 8 | 29 | 20 | 24 | 11 | 6 | 4 | 6 | 4 | 4 | ||||||
| Derivative Liabilities Noncurrent | 62 | 77 | 26 | - | - | - | 0 | - | - | - | - | - | ||||||
| Long Term Debt Noncurrent | - | 1 | 1 | 1 | 1 | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 106 | 88 | 35 | 30 | 21 | 24 | 11 | 6 | 4 | 6 | 4 | 4 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | 25 | 0 | 0 | 0 | 0 | 19 | - | - | - | 0 | - | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 249 | 208 | 204 | 178 | 172 | 152 | 146 | 138 | 137 | 135 | 131 | 127 | ||||||
| Retained Earnings Accumulated Deficit | -262 | -254 | -189 | -172 | -155 | -147 | -139 | -104 | -96 | -89 | -81 | -77 | ||||||
| Stockholders Equity | -13 | -46 | 15 | 6 | 17 | 5 | 7 | 34 | 41 | 46 | 50 | 50 | ||||||
| Liabilities And Stockholders Equity | 93 | 67 | 50 | 36 | 39 | 48 | 37 | 40 | 45 | 52 | 54 | 54 | ||||||
| Series B Preferred Stock | -0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Series A Preferred Stock | - | 0 | - | - | -0 | 0 | - | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 3 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 75 | 75 | 75 | ||||||
| Common Stock Shares Issued | 83 | 71 | 70 | 65 | 60 | 45 | 32 | 26 | 26 | 25 | 24 | 23 | ||||||
| Shares Outstanding | 83 | 71 | 70 | 65 | 60 | 45 | 32 | 26 | 26 | 25 | 24 | 23 | ||||||
| Temporary Equity Shares Outstanding | - | 7 | - | - | - | 0 | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOpus Genetics, Inc. (IRD) — SEC Financial Statements & Analysis
Opus Genetics, Inc. (IRD) is a pharmaceutical preparations company, incorporated in DE. Opus Genetics, Inc. trades on Nasdaq as: IRD. Opus Genetics, Inc. (IRD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Opus Genetics, Inc. carries a market cap of $392.44M, a P/E ratio of -3.65x, a P/B ratio of -30.22x, a P/S ratio of 32.52x, an enterprise value of $303.52M, and an EV/EBITDA multiple of -6.00x. On profitability, it posts an operating margin of -419.32%, a net margin of -891.62%, a Return on Equity (ROE) of -4796.52%, a Return on Assets (ROA) of -163.50%, and a Return on Invested Capital (ROIC) of 822.08%. Per share, it reports EPS of $-1.13, diluted EPS of $-0.97, free cash flow per share of $-0.43, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -5.43% year-over-year, net income growth of 84.66% year-over-year, and EPS growth of 22.57% year-over-year. On the balance sheet, it maintains a current ratio of 12.19x, a quick ratio of 11.87x, working capital of $85.09M, a debt-to-equity ratio of -8.16x, a debt ratio of 1.14, an interest coverage ratio of -186.06x, free cash flow of $-40.67M (TTM), and net debt of $-88.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $392.44M
- P/E TTM
- -3.65x
- EPS TTM
- $-1.13
- P/B TTM
- -30.22x
- ROE TTM
- -4796.52%
- ROA TTM
- -163.50%
- Debt To Equity
- -8.16x
- Free Cash Flow TTM
- $-40.67M
- Net Revenue TTM Growth 1Y
- -5.43%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Opus Genetics, Inc. in?
Opus Genetics, Inc. (IRD) operates in the Pharmaceutical Preparations industry.
What exchange does IRD trade on?
Opus Genetics, Inc. (IRD) trades on the Nasdaq.
Where is Opus Genetics, Inc. incorporated?
Opus Genetics, Inc. is incorporated in DE.
When was Opus Genetics, Inc. (IRD)'s most recent SEC filing?
Opus Genetics, Inc. (IRD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is IRD's market cap?
Opus Genetics, Inc. (IRD) has a market capitalization of $392.44M as of 2026-06-30.
What is IRD's EPS (earnings per share)?
Opus Genetics, Inc. (IRD)'s trailing twelve month EPS is $-1.13 as of 2026-06-30.
What is IRD's ROE (return on equity)?
Opus Genetics, Inc. (IRD)'s trailing twelve month Return on Equity (ROE) is -4796.52% as of 2026-06-30.
What is IRD's ROA (return on assets)?
Opus Genetics, Inc. (IRD)'s trailing twelve month Return on Assets (ROA) is -163.50% as of 2026-06-30.
What is IRD's ROIC (return on invested capital)?
Opus Genetics, Inc. (IRD)'s trailing twelve month Return on Invested Capital (ROIC) is 822.08% as of 2023-09-30.
What is IRD's EV/EBITDA?
Opus Genetics, Inc. (IRD)'s trailing twelve month EV/EBITDA is -6.00x as of 2026-06-30.